Alzheimer's collaboration brings time-course to equation

October 3, 2013 by Aaron Fernandes, Science Network WA
Alzheimer’s collaboration brings time-course to equation
Two hundred participants, including those with early signs of dementia and those diagnosed with Alzheimer’s, were assessed with neuropsychological examination, MRI, and PET scans. Credit: Penn State

Scientists from Western Australia and across the nation have shown the accumulation of a protein in the brain occurs 20 years before symptoms of Alzheimer's occur, in a groundbreaking study that could prove beneficial for early intervention.

Researchers from the Australian Imaging Biomarkers and Lifestyle (AIBL) research group describe the protein Amyloid-Beta (A?) as naturally occurring in the blood and brain. These proteins aggregate to form plaques preceding the onset of Alzheimer's disease.

AIBL's Dr Samantha Burnham says this study is the first time the time-course of A? in the onset of has been quantified statistically.

"There is a general consensus that one of the first things to happen during the onset of Alzheimer's is the accumulation of this plaque in the brain. However we have never known how long before the onset of disease this happens," she says.

"Our objective with this study was to say, if we have identified someone who has reached a certain threshold of A? in the , how long do they have before symptoms of dementia occur?"

The study involved 200 , including 36 with early signs of dementia and 19 already diagnosed with Alzheimer's disease. Participants were assessed every 18 months for almost four years, with neuropsychological examination, MRI, and a PET scan.

At baseline, significantly higher levels of A? were found in patients with AD and those with than in the healthy participants.

"I was tasked with how we could take four year follow-ups from individuals at different stages of the disease and piece them together to give an understanding of what happens throughout the course of the disease," Dr Burnham says.

"All of those individual four year trajectories had to be complied together to get an overall disease level trajectory."

During the follow-ups, 82 per cent of participants showed positive rates of A? accumulation, with deposition estimated to take 19.2 years to reach the levels observed in Alzheimer's disease.

As participants began to show symptoms of AD, the rate of A? deposition slowed towards a plateau.

"There isn't currently any clear explanation for why the accumulation of amyloid beta occurs or why it aggregates and becomes a solid plaque. We just don't know at this stage," Dr Burnham says.

Dr Burnham says the predictions of the rate of preclinical changes and the onset of the clinical phase of AD will facilitate the design and timing of therapeutic interventions aimed at modifying the course of this illness.

"What that means is that we actually have quite a large window for medical interventions to slow the disease," she says.

Explore further: Scientists much closer to developing screening test for early detection of Alzheimer's disease

Related Stories

Scientists much closer to developing screening test for early detection of Alzheimer's disease

May 1, 2013
They identified blood-based biological markers that are associated with the build up of a toxic protein in the brain which occurs years before symptoms appear and irreversible brain damage has occurred.

Pathophysiology may help ID rare, early form of Alzheimer's

July 12, 2012
(HealthDay) -- In dominantly inherited Alzheimer's disease, clinical and biomarker changes occur decades before the expected onset of disease symptoms, according to a study published online July 11 in the New England Journal ...

Blood biomarker could mark severe cognitive decline, quicker progression among Parkinson's patients

September 18, 2013
A genetic mutation, known as GBA, that leads to early onset of Parkinson's disease and severe cognitive impairment (in about 4 to 7 percent of all patients with the disease) also alters how specific lipids, ceramides and ...

Alzheimer's progression tracked prior to dementia

September 23, 2013
For years, scientists have attempted to understand how Alzheimer's disease harms the brain before memory loss and dementia are clinically detectable. Most researchers think this preclinical stage, which can last a decade ...

Fluorescent compounds allow clinicians to visualize Alzheimer's disease as it progresses

September 18, 2013
What if doctors could visualize all of the processes that take place in the brain during the development and progression of Alzheimer's disease? Such a window would provide a powerful aid for diagnosing the condition, monitoring ...

Researchers find earliest known signs of Alzheimer's in people with genetic mutation that causes inherited form

November 5, 2012
Researchers have found the earliest signs of Alzheimer's disease yet detected in a group of people with a rare, inherited form of the disease, according to two Articles published in The Lancet Neurology. The findings raise ...

Recommended for you

Energy storehouses in the brain may be source of Alzheimer's, targets of new therapy

January 23, 2018
Alzheimer's disease, a severely debilitating and ultimately fatal brain disorder, affects millions worldwide. To date, clinical efforts to find a cure or adequate treatment have met with dispiriting failure.

Rocky start for Alzheimer's drug research in 2018

January 19, 2018
The year 2018, barely underway, has already dealt a series of disheartening blows to the quest for an Alzheimer's cure.

Alzheimer's disease: Neuronal loss very limited

January 17, 2018
Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint ...

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.